A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Trial Profile

A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Omacetaxine mepesuccinate (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Refractory anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results (Data cut off 7/2016; n=24), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 19 May 2015 Planned primary completion date changed from 1 Jul 2019 to 1 May 2019 as reported by ClinicalTrials.gov record.
    • 19 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top